Investor Presentaiton

FY23 Revenue spilt by Molecules Paracetamol 46% 38% 22% Metformin Top molecules share 25% 10% Ibuprofen 13% 4%3% Guaifenesin ■FY23 % FY22 % (In Mn) FY23 FY22 Y-0-Y Gr% Paracetamol 20,626 14,282 19% 16% Metformin 9,960 9,410 3%3% Ibuprofen 4,366 4,768 (8%) Methocarbamol Others Guaifenesin 1,616 1,100 Methocarbamol 1,317 1,114 Others 7,233 6,974 2000000 25 25

View entire presentation